The user facility reported to terumo cardiovascular that during cardiopulmonary bypass, during re-warm, they had trouble oxygenating the patient who was noted to be large and septic.No known impact or consequence to the patient.The product was not changed out.Procedure was completed successfully.
|
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on may 15, 2017.The actual sample was not available for evaluation.With the involved lot number not available, evaluation of the retention sample was not carried out.The complaint was not confirmed and a definitive root cause could not be determined.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|